Plain-English translation of NCT07551362 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called , which uses immune cells from a donor that are designed to recognize and attack cancer cells in advanced gastric and gastroesophageal junction cancer. The medication combines two different targets on cancer cells to make it more effective. Researchers want to find the best dose and see how well this treatment works for patients whose cancer has grown despite other treatments.
Advanced stomach cancers often become resistant to standard treatments, and patients with these cancers have limited options. This trial exists to explore whether this new immune cell therapy could offer hope to patients whose cancer has continued to progress despite multiple prior treatments.
You likely qualify if…
You likely don't qualify if…
First, you will receive chemotherapy medications ( and ) over three days to prepare your body for the new immune cells. Then you will receive three infusions of the new medication on specific days. Throughout the trial, you will have blood tests, imaging scans, and clinic visits to monitor how well the treatment is working and to check for any side effects. The trial will track your response to treatment and how long the effects last.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China